Baucus and Grassley say the FDA suppresses scientific dissent

Share this article:
Sens. Max Baucus (D-MT) and Chuck Grassley (R-IA) say the FDA continues to suppress scientific dissent and punish agency staff who raise safety issues. In a letter to the FDA commissioner, the senators say an unnamed senior FDA official has been sidelined after voicing concerns about the safety of GlaxoSmithKline's diabetes drug Avandia.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.